SCHEMBL25812023

SCHEMBL25812023

CCN(CC)CCN(I)C(=O)c1ccc2[nH]c3c(c2c1)CCCC3

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.57
KMT2A Q03164 7/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
MAPT P10636 8/20 0.55
KDM4E B2RXH2 8/20 0.55
LMNA P02545 6/20 0.55
ALDH1A1 P00352 5/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
CASP1 P29466 2/20 0.51
TP53 P04637 2/20 0.51
F2 P00734 1/20 0.49
POLB P06746 1/20 0.48
MAPK1 P28482 2/20 0.47
USP2 O75604 1/20 0.47
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
ALOX15 P16050 1/20 0.47
CASP7 P55210 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25812030 0.98 MEN1 (0.55) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL25811259 0.80 TP53 (0.72) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL25811262 0.78 TP53 (0.69) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL25815092 0.77 KDM4E (0.59) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL25812069 0.76 CYP19A1 (0.44) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL25814506 0.76 TLR9 (0.44) MEN1KMT2AMAPTKDM4ELMNA
SCHEMBL25813810 0.75 KDM4E (0.56) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL29059075 0.75 MEN1 (0.61) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL30523150 0.75 MEN1 (0.61) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL4258762 0.74 MAPT (0.68) MEN1KMT2ANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 MEN1 3841/4885KMT2A 981/4885NPC1 1099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.